|drug3259||Standard treatment for COVID-19 Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the COVID-19 (risk or protective factors), in out-patients suspected of being infected with precocious home monitoring. The primary event defining the aggravation will be then: hospitalization (medicine, resuscitation) or death. The studied potential risk factors will be mainly: - Socio-demographic: age, sex, place of residence or income - Comorbidities - Clinical signs: asthenia, dyspnea (kinetics)… - Drugs other than those related to the infection For this research project, this study needs to use the patient's data of the COVIDADOM cohort (patients suspected of being infected with SARS-CoV-2 with home monitoring) and will collect some supplementary data (clinical and biological). All these data will be integrated and analyzed in the PREDIMED clinical data lake platform (The implementation of PREDIMED has been approved by the French authority in terms of GDPR, CNIL, on October 10, 2019).
Description: The event defining the aggravation will be: hospitalization (medicine, resuscitation) or death The main potential risk factors will be the following: Socio-demographic: age, sex, place of residence, CSP and income. Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc. Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain… Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)Measure: Identify the factors associated with the worsening of the COVID19 Time: 30 days
Description: Clinical and monitoring data of the the COVIDADOM cohort and of the COVIDADOMEVA case report form (CRF)Measure: Describe the clinical care pathway of patients from Day 0 to Day 14 Time: 30 days
Description: Health status patient (stay at home, hospitalization or death)Measure: Describe the health status at Day 30 Time: 30 days
Description: EQ5D-5L scoreMeasure: Describe the quality of life during the disease Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports